Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
about
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsAsking the right questions: developing evidence-based strategies for treating HIV in women and childrenAdherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureIncidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaborationHIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.Human immunodeficiency virus infection and the liverNevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African womenAssociation of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.Drug-induced liver injury: a summary of recent advances.Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility.
P2860
Q28478275-39C698C0-A39A-4B60-A560-DF2175D75290Q28743488-5FE7A996-0610-494C-85F0-93CB9806E608Q33814942-B95E0945-BEC5-4606-B856-321C647AD907Q34444338-7154669A-6401-4B0B-85B3-074FC6CDA4F1Q35146943-06DEF0C6-5636-4096-A2CA-ADCD38FEA24EQ35409929-7379AD92-9794-4C16-A6DB-6B649FC82A9FQ35852627-C3745CE9-F6C1-40C3-92EC-2A3E01571CB0Q35875848-79F9B1C0-9F58-41BD-AF4B-CFA6616A2C45Q36422444-B8CC2BF6-7383-431D-87DE-103B3BD29571Q36508979-40770BDA-FEF6-4995-A21D-F2F183FFC01DQ37867695-3065AD3E-DFF7-489F-97E8-B4DDD347E2D3Q38630880-6B3E14F3-F863-4F0C-8374-92B51B98029BQ39553824-6B125955-3A65-434A-BFC0-CFBDCD588903Q40130609-F3FF83F3-8CC4-4C2E-8156-9641EDA45DD5
P2860
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@ast
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@en
type
label
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@ast
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@en
prefLabel
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@ast
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@en
P2093
P2860
P50
P356
P1476
Incidence and risk factors of ...... ogram, Abidjan, Côte d'Ivoire.
@en
P2093
Aristophane K Tanon
Besigin Tonwe-Gold
Didier K Ekouevi
Gédéon Bédikou
Patrick A Coffie
P2860
P2888
P356
10.1186/1471-2334-10-188
P577
2010-06-24T00:00:00Z
P5875
P6179
1034255061